登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07649928,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Women of childbearing potential who agree to use at least one medically recognized method for contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment and for 1 year after the last treatment, and have a negative pregnancy test result at screening;
入选标准第 9 条
Brain metastases, except for individuals who have received systematic and radical therapy (radiotherapy or surgery) for brain metastases, demonstrated radiologically stable disease for at least 4 weeks, discontinued systemic corticosteroids for more than 2 weeks, and remain asymptomatic.
排除标准第 4 条
Received prior targeted therapy targeting RAS-G12V within 4 weeks before the first dose, or within 5 half-lives of the therapeutic agent, whichever is longer;
排除标准第 6 条
ECOG score: 0-1;
入选标准第 6 条
Individuals with at least one measurable lesion (defined per RECIST v1.1 as a lesion with the longest diameter ≥10 mm, or a lymph node with a short axis of ≥15 mm); lesions that have undergone radiotherapy or other local therapies are not considered target lesions unless they demonstrate clear progression;
入选标准第 5 条
Malignant tumors other than those under investigation in this study (except for cured thyroid cancer, skin basal cell carcinoma, or cervical carcinoma in situ) within the past 5 years;
排除标准第 2 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07649928,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years, regardless of gender; Available fresh or archived tumor tissue samples (within the past 5 years) for testing at screening; Individuals with histologically or cytologically confirmed advanced solid tumors for whom no standard therapy exists, who are refractory to standard therapy, or who are deemed unsuitable for standard therapy by the investigator. Tumor types include but are not limited to: pancreatic cancer, colorectal cancer, non-small cell lung cancer, intrahepatic cholangiocarcinoma, gallbladder cancer, ovarian cancer, endometrial cancer, and intestinal cancer; RAS G12V mutation (KRAS/NRAS/HRAS) and positivity for HLA-DPB1*03:01, *14:01, *25:01, or *104:01; Individuals with at least one measurable lesion (defined per RECIST v1.1 as a lesion with the longest diameter ≥10 mm, or a lymph node with a short axis of ≥15 mm); lesions that have undergone radiotherapy or other local therapies are not considered target lesions unless they demonstrate clear progression; ECOG score: 0-1; Expected survival greater than 3 months; Adequate hematological and organ function, as evidenced by the following laboratory tests (the individual must not have received a blood transfusion, long-acting EPO or long-acting G-CSF within 14 days before study treatment, or not have received short-acting EPO or short-acting G-CSF within 7 days before study treatment): 1) hematology: absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, platelet count (PLT) ≥100 × 10⁹/L, hemoglobin (Hb) ≥90 g/L; 2) liver function test: both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × upper limit of normal (ULN), total bilirubin (TBIL) ≤1.5 × ULN. Exceptions: liver metastasis, AST and/or ALT ≤5 × ULN; Gilbert's syndrome, TBIL ≤3 × ULN; pancreatic head cancer or biliary obstruction, TBIL ≤3 × ULN; 3) kidney function test: creatinine clearance (CrCL) ≥50 mL/min (by Cockcroft-Gault formula); 4) coagulation function test: activated partial thromboplastin time (APTT) ≤1.5 × ULN and international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN; 5) echocardiography: left ventricular ejection fraction (LVEF) ≥50%; eligibility for enrollment of individuals with out-of-range laboratory results should be determined at the investigator's discretion. Women of childbearing potential who agree to use at least one medically recognized method for contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment and for 1 year after the last treatment, and have a negative pregnancy test result at screening; Prior antitumor treatment-related adverse events (AEs) (per NCI-CTCAE v6.0) have resolve to ≤ Grade 1 at screening, except for alopecia, Grade 2 hypothyroidism, and non-clinically significant or asymptomatic laboratory abnormalities; Individuals who fully understand the informed consent information, agree to participate in this clinical study, and voluntarily sign the Informed Consent Form (ICF).排除标准:Exclusion Criteria:
Individuals with the following tumors: Malignant tumors other than those under investigation in this study (except for cured thyroid cancer, skin basal cell carcinoma, or cervical carcinoma in situ) within the past 5 years; Meningeal metastases; Brain metastases, except for individuals who have received systematic and radical therapy (radiotherapy or surgery) for brain metastases, demonstrated radiologically stable disease for at least 4 weeks, discontinued systemic corticosteroids for more than 2 weeks, and remain asymptomatic. Individuals with the following conditions: Received prior targeted therapy targeting RAS-G12V within 4 weeks before the first dose, or within 5 half-lives of the therapeutic agent, whichever is longer; Participation in other clinical studies involving an investigational product within 4 weeks before the first dose; Use of systemic antitumor therapy (including but not limited to chemotherapy, radiotherapy, biotherapy, immunotherapy, and cell therapy) within 4 weeks or 5 half-lives (whichever is shorter) before the first dose; Receipt of major surgery without complete recovery within 4 weeks before the first dose, or planning to undergo major surgery during the study; Receipt of systemic immunosuppressants or systemic corticosteroids within 1 week before the first dose; Receipt of live-attenuated vaccines within 4 weeks before the first dose, or planning to receive such vaccines during the study; Planning to receive any other systemic antitumor therapy (chemotherapy, radiotherapy, biotherapy, immunotherapy, cell therapy, etc.) during the study; Symptomatic ascites, pleural effusion or pericardial effusion requiring drainage at screening, or history of drainage for serous effusion within 4 weeks before the first dose; History of clinically significant cardiovascular disorders at screening, including but not limited to congestive heart failure (NYHA Class ≥ II), unstable angina, myocardial infarction, stroke or transient ischemic attack (TIA), severe arrhythmias (including but not limited to atrial fibrillation or paroxysmal supraventricular tachycardia, complete left bundle branch block or third-degree atrioventricular block with clinical significance and requiring clinical intervention), or poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg) within 6 months before enrollment; QT interval corrected by Fridericia's formula (QTcF) ≥470 ms; History of severe infection within 4 weeks before the first dose; active infection requiring therapeutic intravenous antibiotics within 2 weeks before the first dose. Use of prophylactic antibiotics is not an exclusion criterion; Active autoimmune diseases, or any conditions requiring systemic corticosteroids or immunosuppressants (prednisone at ≥20 mg/day or an equivalent dose) at screening; History or evidence of clinically unstable or poorly controlled disorders (including but not limited to cardiac, pulmonary, renal, hepatic, metabolic or hematological disorders) at screening; History of severe allergy or known hypersensitivity to the investigational product or its components; Organ transplantation, allogeneic stem cell transplantation or renal replacement therapy in the past or at screening; Pulmonary embolism, pulmonary fibrosis, interstitial lung disease or acute lung disease in the past or at screening; Positivity for Treponema pallidum antibody, positivity for human immunodeficiency virus (HIV) antibody, or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening. Definition of active HBV infection: positivity for hepatitis B surface antigen (HBsAg), and HBV DNA above the ULN; definition of active HCV infection: positivity for hepatitis C antibody, and HCV RNA above the ULN. Such conditions unsuitable for enrollment as judged by the investigator; Other circumstances inappropriate for participation in this study as considered by the investigator.
引自 ClinicalTrials.gov, NCT07649928, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07649928,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。